Newsquawk Logo

Biogen (BIIB) CEO says LEQEMBI IQLIK is eligible for part D reimbursement, but won't be fully reimbursed until January 2027

Biogen's announcement regarding LEQEMBI IQLIK being eligible for Part D reimbursement is significant as it opens a revenue stream, though full reimbursement won't commence until January 2027.

Newsquawk StaffPublished On the live feed at — 11 more headlines followed before this page went public
Newsquawk headlinesUTC

"IRNA: Indications of an understanding during the first round of negotiations with the United States", Al Arabiya reports citing IRNA

Renault (RNO FP) sales in Germany have been reportedly halted due to a patent violation suit, via WiWo

Biogen (BIIB) CEO says LEQEMBI IQLIK is eligible for part D reimbursement, but won't be fully reimbursed until January 2027

Under Armour (UAA) raises FY adj. operating income outlook

Kazakhstan's CPC blend February oil exports could reportedly decline by 35% to 1.1mln bpd

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

The delayed timeline could impact investor sentiment and stock performance in the interim, especially as market expectations adjust over this period. This development also invites scrutiny on the company's near-term earnings outlook and how it positions Biogen against peers in the biotech sector.

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.